Clinical Trials

Study Title

Phase 3 neoadjuvant study of T-DXd or T-DXd followed by THP versus ddAC-THP in participants with early-stage high-risk HER2+ breast cancer (Destiny)

Purpose

To demonstrate superiority of neoadjuvant T-DXd alone or in sequence with THP relative to ddAC-THP by assessment of pCR (ypT0/Tis ypN0) using central evaluation in participants with HER2-positive EBC

Eligibility

Study Process